A First In Human Randomised, Double-Blind, Placebo-Controlled Study Of Single Ascending Doses In Healthy Male Volunteers And Repeated Ascending Dose In Asthmatic Patients Followed By A 3-Way Cross-Over, Placebo-Controlled, Single-Dose In Copd Patients To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CHF6366
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2018
At a glance
- Drugs CHF-6366 (Primary) ; Umeclidinium; Vilanterol
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions; First in man
- Sponsors Chiesi Farmaceutici SpA
- 27 Nov 2018 Planned End Date changed from 28 Aug 2018 to 28 Jun 2019.
- 27 Nov 2018 Planned primary completion date changed from 28 Aug 2018 to 28 Mar 2019.
- 03 Jan 2018 Planned End Date changed from 20 Jul 2019 to 28 Aug 2018.